Bone marrow biopsy adds little to PET/CT staging of Hodgkin's

(HealthDay)—For patients with treatment-naive Hodgkin's lymphoma (HL) staged using [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), routine bone marrow biopsy (BMB) has little or no therapeutic consequence, according to research published online Nov. 13 in the Journal of Clinical Oncology.

Tarec Chistoffer El-Galaly, M.D., of Aarhus University Hospital in Denmark, and colleagues conducted a involving 454 patients with newly diagnosed HL to determine whether BMB adds useful information to PET/CT staging.

Of the patients, 18 percent had focal skeletal PET/CT and 6 percent had positive BMB. Among patients assessed as having stage I to II disease by PET/CT staging, the researchers found that none were positive for BMB. Five patients assessed as being stage III before BMB were upstaged by BMB, but none of the patients were allocated to a different treatment based on the results of BMB. For identification of positive and negative BMBs, focal skeletal PET/CT lesions had a sensitivity of 85 percent and a specificity of 86 percent; the sensitivity and specificity for BMB results were 28 and 99 percent, respectively.

"To the best of our knowledge, this is the largest study to date examining the value of BMB in patients with HL who are undergoing PET/CT staging," the authors write. "The added diagnostic value from routine BMB was minimal, and positive BMB findings implied upstaging in only five patients from to stage IV disease of a total of 454 included patients."

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Life expectancy prolonged for esophageal cancer patients

Jun 04, 2012

For those with esophageal cancer, initial staging of the disease is of particular importance as it determines whether to opt for a curative treatment or palliative treatment. Research presented in the June issue of The Journal of ...

PET more sensitive than CT for merkel cell carcinoma

May 15, 2012

(HealthDay) -- Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) is significantly more sensitive and equally specific compared with traditional computed tomography (CT) imaging for ...

Recommended for you

Gene test aids cancer profile

7 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

Nov 26, 2014

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.